US Medical Affairs Doctoral and PharmD Intern, GI Oncology
AstraZeneca
Summary
We are looking for PhD and PharmD students studying life sciences and/or pharmaceutical sciences for a 12-week internship role at our site in Gaithersburg, MD from May 24, 2027 to August 13, 2027.
Job description
Position Description
- Analyze and synthesize medical insights from multiple sources to inform medical strategy and tactics
- Develop external-facing scientific materials to support ongoing medical education efforts
- Explore internal technologies to enhance medical affairs efficiency and impact within the USMA- Oncology GI team
Requirements
- PhD and PharmD students studying life sciences and/or pharmaceuticals
- Strong scientific background is required
- Analytical and presentation skills are preferred
- Prior oncology research experience is a plus
- Enthusiasm for collaboration, cross-functional projects, public speaking, and presentation design
- Candidates must have an expected graduation date after August 2027
- US Work Authorization is required at time of application
- This role will not be granting OPT support
- Ability to report onsite to Gaithersburg, MD site 3 days per week
- This role will not provide relocation assistance
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.